An update on biomarker in axial spondyloarthritis

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023728%3A_____%2F16%3AN0000003" target="_blank" >RIV/00023728:_____/16:N0000003 - isvavai.cz</a>

Result on the web

<a href="https://doi.org/10.1016/j.autrev.2016.02.002" target="_blank" >https://doi.org/10.1016/j.autrev.2016.02.002</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.autrev.2016.02.002" target="_blank" >10.1016/j.autrev.2016.02.002</a>

Result language

angličtina

Original language name

An update on biomarker in axial spondyloarthritis

Original language description

Axial spondyloarthritis is a chronic inflammatory disease with the onset at a young age, and, if undiagnosed and untreated, it may result in permanent damage and lifelong disability. Rates of early diagnosis have improved, due in particular to the addition of magnetic resonance imaging into the diagnostic armamentaria; however, it is costly, not widely available, and requires experienced readers to interpret the findings. In addition to clinical measures and imaging techniques, biomarkers that will be described in this review may represent useful tools for diagnosis, monitoring disease activity and outcomes as well as therapeutic responses. Currently, HLA-B27 remains the best genetic biomarker for making a diagnosis, while CRP currently appears to be the best circulating measure for assessing disease activity, predicting structural progression and therapeutic response. Interestingly, key molecules in the pathogenesis of the disease and essential therapeutic targets, such as tumour necrosis factor (TNF)α, interleukin (IL)-17 and IL-23, show only limited association with disease characteristics or disease progression. Some genetic biomarkers and particularly anti-CD74 antibodies, may become a promising tool for the early diagnosis of axSpA. Further biomarkers, such as matrix metalloproteinases (MMP)-3, calprotectin (S100A8/9), vascular endothelial growth factor (VEGF), C-terminal telopeptide of type II collagen (CTX-II) or dickkopf-1 (DKK-1), are not sufficient to reflect disease activity, but may predict spinal structural progression. In addition, recent data have shown that monitoring calprotectin might represent a valuable biomarker of therapeutic response. However, all of these results need to be confirmed in large cohort studies prior to use in daily clinical practice.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30226 - Rheumatology

Project

—

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2016

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

AUTOIMMUNITY REVIEWS

ISSN

1568-9972

e-ISSN

—

Volume of the periodical

15

Issue of the periodical within the volume

6

Country of publishing house

NL - THE KINGDOM OF THE NETHERLANDS

Number of pages

9

Pages from-to

501-509

UT code for WoS article

000375499700002

EID of the result in the Scopus database

2-s2.0-84959066372